Sort
82,697 grants matching “vaccine development”
Good Manufacturing Practices Master Cell and Working Cell Banks and GMP Pilot Lot of Prototype Shigella flexneri 2a live vector expressing enterotoxigenic E. coli antigens, CVD 1208S 122
$1,062,611Eileen M. Barry · University Of Maryland Baltimore · R01 · FY2018 · AI
Immunotherapeutic Interventions of AIDS and Cancer
$1,062,472Barbara Felber · Division Of Basic Sciences - Nci · ZIA · FY2017 · CA
University of California, San Diego Clinical Trial Unit
$1,062,445Stephen A Spector · University Of California, San Diego · U01 · FY2010 · AI
Project-002
$1,062,427Arnab Basu · Georgia State University · U19 · FY2018 · AI
Dengue Epitope Vaccine,Tetravalent &MHCII-Targeted
$1,062,345Johns Hopkins University · U19 · FY2003 · AI
Structure-Based Design of Drugs and Vaccines for Target*
$1,062,312Rutgers The St Univ Of Nj New Brunswick · P01 · FY2005 · GM
An HIV Prevention Program for Mochudi, Botswana
$1,062,286Myron E Essex · Harvard School Of Public Health · R01 · FY2010 · AI
Understanding and Mimicking TCR Recognition with Therapeutic Monoclonal Antibodies.
$1,062,000David A Scheinberg · Sloan-Kettering Inst Can Research · R35 · FY2025 · CA
Understanding and Mimicking TCR Recognition with Therapeutic Monoclonal Antibodies.
$1,062,000David A Scheinberg · Sloan-Kettering Inst Can Research · R35 · FY2021 · CA
Salmonella Group C as part of a multivalent Salmonella vaccine
$1,061,750Sharon Mei Tennant · University Of Maryland Baltimore · U19 · FY2016 · AI
Establishment/Maintenance of Biomedical Research Colony
$1,061,517Thomas J. Rowell · University Of Louisiana At Lafayette · U42 · FY2010 · RR
Clinical Evaluation of a Personalized Vaccine Immunotherapy in Combination with Checkpoint Inhibitors for Triple Negative Breast Cancer
$1,061,403Christopher D Pack · Metaclipse Therapeutics Corporation · R44 · FY2021 · CA
Factors Contributing To Immune-Enhanced Disease In The Pathogenesis of RSV
$1,061,274Barney Graham · National Institute Of Allergy And Infectious Diseases · ZIA · FY2017 · AI
Center of Biomedical Research Excellence in Matrix Biology Phase 3
$1,061,250Julia T Oxford · Boise State University · P30 · FY2025 · GM
Center of Biomedical Research Excellence in Matrix Biology Phase 3
$1,061,250Julia T Oxford · Boise State University · P30 · FY2024 · GM
Malaria Parasite Ligands And Host Cell Receptors
$1,060,999Louis Miller · National Institute Of Allergy And Infectious Diseases · ZIA · FY2016 · AI
Non-Human Primate Core (NHP Core)
$1,060,944Koen K Van Rompay · Duke University · P01 · FY2015 · AI
Tuberculosis Research Unit
$1,060,900W. Henry Henry Boom · Case Western Reserve University · N01 · FY2009 · AI
Miami HIV/AIDS Clinical Therapeutic and Vaccine Trial Unit
$1,060,788Margaret A Fischl · University Of Miami School Of Medicine · UM1 · FY2013 · AI
Core B_Silvestri
$1,060,779Guido Silvestri · Scripps Research Institute, The · P01 · FY2022 · AI
Wisconsin National Primate Research Center Support
$1,060,757Martin Cadwallader · University Of Wisconsin-Madison · P51 · FY2009 · RR
Evolutionary Analysis and Comparative Genomics of Protein Superfamilies
$1,060,673Aravind Iyer · National Library Of Medicine · ZIA · FY2014 · LM
Molecular approaches to understand vector-host and vector-pathogen interactions
$1,060,605Jesus Valenzuela · National Institute Of Allergy And Infectious Diseases · ZIA · FY2016 · AI
Structural Approches to HIV-1 Immunogen Design for BNAb Generation
$1,060,577Ellis L Reinherz · Dana-Farber Cancer Inst · U19 · FY2012 · AI
The paradox of flavivirus antigenic non-reciprocity
$1,060,551Thomas C. Friedrich · University Of Wisconsin-Madison · R01 · FY2025 · AI